Machine Learning Prediction of Respiratory Muscle Changes and Ventilatory Responses After Incretin-Based Therapy in Obesity
2026년 6월 17일 업데이트: Buket AKINCI, Biruni University
Prediction of Changes in Pulmonary Function, Respiratory Muscle Performance, and Ventilatory Responses Following Incretin-Based Therapy in Individuals With Obesity Using Machine Learning
This study aims to evaluate changes in respiratory function, respiratory muscle performance, and ventilatory responses following incretin-based therapy in individuals with obesity, and to identify predictors of these changes through the application of machine learning methods.
연구 개요
상태
상태
아직 모집하지 않음
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
관찰
등록 (추정된)
등록
48
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
연구 연락처
- 이름: Şafak Yiğit, PhD
- 전화번호: +90 5309634910
- 이메일: safakyigit90@gmail.com
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
건강한 자원 봉사자를 받아들입니다
예
샘플링 방법
비확률 샘플
연구 인구
Individuals with obesity using incretin based therapy
설명
Inclusion Criteria:
- Individuals aged 25-60 years
- Individuals with a body mass index (BMI) ≥ 30 kg/m² according to the World - Health Organization (WHO) classification of obesity
- Individuals who voluntarily agree to participate in the study
Exclusion Criteria:
Charlson Comorbidity Index (CCI) score ≥ 3 Uncontrolled arrhythmia, hypertension, heart failure, diabetes mellitus, or unstable angina pectoris Cognitive, orthopedic, or neurological conditions that may interfere with study assessments or treatment procedures History of lower extremity injury or surgery within the previous 6 months Diagnosis of diabetes mellitus with complications such as nephropathy, retinopathy, or neuropathy Presence of chronic respiratory disease Acute infection at the time of assessment Middle ear pathologies (e.g., tympanic membrane rupture or otitis) History of spontaneous or traumatic pneumothorax Current smoking Pregnancy STOP-Bang score ≥ 3 Participation in a structured weight-loss diet program or receipt of medical treatment for weight reduction during the assessment period History of endoscopic weight-loss procedures and/or bariatric surgery within the previous 12 months
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum Inspiratory Pressure (MIP)
기간: Baseline to 3 months
|
Maximum inspiratory pressure (MIP) assessment will be performed using an intraoral pressure measuring device (MicroRPM, Micro Medical; UK) in accordance with ATS and ERS criteria.
Measurements will be taken with a nasal clip in place and in a seated position.
To prevent the risk of infection, a disposable mouthpiece and filter will be used for each participant.
For maximum inspiratory pressure (MIP) measurement, maximal inspiration will be applied orally for a few seconds and the values will be recorded.
Measurements will be repeated three times, and the best value that meets the measurement standard will be recorded in cmH2O.
For the measurement to be considered valid, the difference between the two highest measurements must be less than 10%.
When evaluating inspiratory muscle strength, age and gender-specific reference ranges will be considered.
The reference equations developed by Black and Hyatt will be used in the interpretation of the measurements.
|
Baseline to 3 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum Expiratory Pressure (MEP)
기간: Baseline to 3 months
|
Maximum expiratory pressure (MEP) will be measured using an intraoral pressure measuring device (MicroRPM, Micro Medical; UK) in accordance with ATS and ERS criteria.
Measurements will be performed with a nasal clip in place and in a seated position.
To prevent the risk of infection, a disposable mouthpiece and filter will be used for each participant.
Maximum expiratory pressure (MEP) will be measured by applying maximal exhalation for a few seconds and recording the values.
Measurements will be repeated three times, and the best value that meets the measurement standard will be recorded in cmH2O.
For the measurement to be considered valid, the difference between the two highest measurements must be less than 10%.
When evaluating respiratory muscle strength, age and gender-specific reference ranges will be considered.
Reference equations developed by Black and Hyatt will be used to interpret the measurements.
|
Baseline to 3 months
|
|
Forced vital capacity (FVC)
기간: Baseline to 3 months
|
Forced vital capacity (FVC) will be assessed using pulmonary function tests (PFTs).
The assessment will be performed using the "COSMED Spiropalm 6MWT" (COSMED; Italy) device and integrated PFT software, in accordance with ATS and European Respiratory Society (ERS) criteria (ATS&ERS, 2002).
The assessment will be conducted in a seated position with back support.
To prevent the risk of infection, a disposable mouthpiece and filter will be used for each participant.
Values will be recorded in liters and as a percentage (%) of the expected value.
Measurements will be repeated three times, and the best value meeting the measurement standard will be recorded.
|
Baseline to 3 months
|
|
Forced expiratory volume in the first second (FEV1)
기간: Baseline to 3 months
|
Forced expiratory volume in the first second (FEV1) will be assessed using pulmonary function tests (PFTs).
The assessment will be performed using the "COSMED Spiropalm 6MWT" (COSMED; Italy) device and integrated PFT software, in accordance with ATS and European Respiratory Society (ERS) criteria (ATS&ERS, 2002).
The assessment will be conducted in a seated position with back support.
To prevent the risk of infection, a disposable mouthpiece and filter will be used for each participant.
Values will be recorded in liters and as a percentage (%) of the expected value.
Measurements will be repeated three times, and the best value meeting the measurement standard will be recorded.
|
Baseline to 3 months
|
|
FEV1/FVC
기간: Baseline to 3 months
|
FEV1/FVC will be assessed using pulmonary function tests (PFTs), and the assessment will be performed according to ATS and European Respiratory Society (ERS) criteria using the "COSMED Spiropalm 6MWT" (COSMED; Italy) device and integrated PFT software (ATS&ERS, 2002).
The assessment will be performed in a seated position with back support.
To prevent the risk of infection, a disposable mouthpiece and filter will be used for each participant.
The values will be recorded in liters and as a percentage (%) of the expected value.
Measurements will be repeated three times, and the best value that meets the measurement standard will be recorded.
|
Baseline to 3 months
|
|
Respiratory Muscle Endurance
기간: Baseline to 3 months
|
Participants' respiratory muscle endurance will be assessed using an inspiratory muscle training device (POWERbreathe® K-SerieS-K3, POWERbreathe International Ltd, UK).
Measurements will be taken in a seated position with the device placed in the mouth using a nose clip.
The assessment will be conducted using an increasing threshold loading protocol.
At the start of the test, the threshold pressure will be set to 20% of the individual's MIP (maximum inspiratory pressure).
The individual will be asked to breathe 30 times over two minutes.
Individuals who tolerate this level will proceed to the next step, gradually increasing the pressure to 40%, 60%, 80%, and 100% respectively.
Oxygen saturation and pulse rate will be recorded before and after the test using a pulse oximeter.
|
Baseline to 3 months
|
|
Functional capacity
기간: Baseline to 3 months
|
Participants' exercise capacity will be assessed using the Spiropalm 6MWT (Cosmed, Italy) six-minute walk test (6MWT) according to American Thoracic Society (ATS) criteria.
This device is a comprehensive system that includes an integrated pulse oximeter for monitoring oxygen saturation during the test and allows for measurement of heart rate, minute ventilation (VE), and respiratory pattern during walking.
The Spiropalm 6MWT meets all technical criteria set by the ATS for the 6MWT and is also compliant with ATD/ASD spirometry standards.
The test will be conducted in a 30-meter straight corridor in an enclosed area.
Participants will rest for at least 10 minutes before starting the test.
Following the rest period, heart rate, blood pressure, and oxygen saturation measurements will be taken.
In addition, dyspnea and leg fatigue levels will be assessed using the Modified Borg Scale (0-10).
Participants will be asked to walk at a pace faster than their normal walking
|
Baseline to 3 months
|
|
Ventilation (VE)
기간: Baseline to 3 months
|
During the 6MWT will be measured using a Spiropalm device.
|
Baseline to 3 months
|
|
Peak respiratory reserve (BRpeak)
기간: Baseline to 3 months
|
During the 6MWT, peak respiratory reserve (BRpeak) will be measured using a Spiropalm device.
|
Baseline to 3 months
|
|
Peak ventilation (VEpeak)
기간: Baseline to 3 months
|
During the 6MWT, peak ventilation (VEpeak) will be measured using a Spiropalm device.
|
Baseline to 3 months
|
|
Inspiratory capacity (IC)
기간: Baseline to 3 months
|
During the 6MWT, inspiratory capacity (IC) will be measured using a Spiropalm device.
|
Baseline to 3 months
|
|
Waist Index (WI) Adjusted for Weight
기간: Baseline to 3 months
|
This will be calculated according to the following formula based on waist circumference and weight measurements.
|
Baseline to 3 months
|
|
Skeletal Muscle Mass Index (SMMI)
기간: Baseline to 3 months
|
Skeletal Muscle Mass Index (SMMI) is calculated by dividing an individual's total skeletal muscle mass (kg) by the square of their height in meters (m²) (kg/m²).
|
Baseline to 3 months
|
|
Body Roundness Index (BRI)
기간: Baseline to 3 months
|
The Body Roundness Index (BRI) will be calculated using the individual's waist circumference (cm) and height (m) according to the standard formula defined in the literature.
The BRI value will be evaluated as an indicator of body fat distribution and abdominal obesity level.
|
Baseline to 3 months
|
|
Body muscle mass
기간: Baseline to 3 months
|
Participants' body muscle mass (kg) and body muscle percentage (%) will be measured using Bioelectrical Impedance Analysis (BIA).
Individuals will be informed about the test protocol and instructed to fast for 8-12 hours before the measurement, to arrive with an empty bladder, and to avoid fluids, food, and strenuous physical activity.
Measurements will be taken at a room temperature of 25°C, during the daytime, and participants will be asked to remove their shoes, socks, and all metal objects before stepping onto the device barefoot.
|
Baseline to 3 months
|
|
Body fat mass
기간: Baseline to 3 months
|
Participants' body fat mass (kg), body fat percentage (%) will be measured using Bioelectrical Impedance Analysis (BIA).
Individuals will be informed about the test protocol and instructed to fast for 8-12 hours before the measurement, to arrive with an empty bladder, and to avoid fluids, food, and strenuous physical activity.
Measurements will be taken at a room temperature of 25°C, during the daytime, and participants will be asked to remove their shoes, socks, and all metal objects before stepping onto the device barefoot.
|
Baseline to 3 months
|
|
Waist circumference
기간: Baseline to 3 months
|
Waist circumference will be measured with a non-stretch measuring tape.
The measurement will be taken three times at the level of the navel with the patient in an upright position during exhalation, with both feet bearing equal weight.
The average value will be recorded in centimeters (cm).
|
Baseline to 3 months
|
|
Daily step count
기간: Baseline to 3 months
|
Participants' physical activity levels will be assessed using a wearable activity monitor.
The device uses a six-axis sensor (accelerometer and gyroscope) to temporarily store data on the user's lifestyle and physical activity profile in its memory for the duration of wear.
The wearable activity monitor will track participants' daily step counts.
Participants will be asked to wear the activity monitor continuously on their left wrist for at least 72 hours, excluding sleep or bathing hours.
|
Baseline to 3 months
|
|
Fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c)
기간: Baseline to 3 months
|
For the glucose profile of participants after 12 hours of fasting, fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) levels will be measured.
|
Baseline to 3 months
|
|
Lipid profile
기간: Baseline to 3 months
|
Participants will have their lipid profile measured after a 12-hour fast, including high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglyceride levels.
|
Baseline to 3 months
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
연구 시작
2026년 7월 1일
기본 완료 (추정된)
기본 완료
2026년 7월 1일
연구 완료 (추정된)
연구 완료
2026년 7월 30일
연구 등록 날짜
최초 제출
최초 제출
2026년 6월 17일
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
2026년 6월 17일
처음 게시됨 (실제)
처음 게시됨
2026년 6월 23일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
2026년 6월 23일
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
2026년 6월 17일
마지막으로 확인됨
마지막으로 확인됨
2026년 6월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2026ML
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
미정
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .